Loading clinical trials...
Loading clinical trials...
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Conditions
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Placebo: NaCl 0.9%
Locations
4
Malaysia
Ipoh, Perak, Malaysia
Kuala Lumpur, Malaysia
Kuching, Sarawak, Malaysia
Negeri Sembilan, Malaysia
Start Date
December 2, 2010
Primary Completion Date
September 28, 2012
Completion Date
January 1, 2013
Last Updated
March 25, 2022
NCT06579755
NCT07007585
NCT06665035
NCT06388785
NCT07432061
NCT06741683
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions